![logo](/logos/INAB.webp)
IN8bio, Inc.
NASDAQ:INAB
0.3 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | IN8bio, Inc. |
Symbool | INAB |
Munteenheid | USD |
Prijs | 0.304 |
Beurswaarde | 14,223,218 |
Dividendpercentage | 0% |
52-weken bereik | 0.301 - 2.48 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Tai-Wei Ho |
Website | https://in8bio.com |
An error occurred while fetching data.
Over IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)